Literature DB >> 15901791

Postadolescent changes in regional cerebral protein synthesis: an in vivo study in the FMR1 null mouse.

Mei Qin1, Julia Kang, Thomas V Burlin, Chunhui Jiang, Carolyn Beebe Smith.   

Abstract

Methylation-induced transcriptional silencing of the fragile X mental retardation-1 (Fmr1) gene leads to absence of the gene product, fragile X mental retardation protein (FMRP), and consequently fragile X syndrome (FrX), an X-linked inherited form of mental retardation. Absence of FMRP in Fmr1 null mice imparts some characteristics of the FrX phenotype, but the precise role of FMRP in neuronal function remains unknown. FMRP is an RNA-binding protein that has been shown to suppress translation of certain mRNAs in vitro. We applied the quantitative autoradiographic L-[1-14C]leucine method to the in vivo determination of regional rates of cerebral protein synthesis (rCPS) in adult wild-type (WT) and Fmr1 null mice at 4 and 6 months of age. Our results show a substantial decrease in rCPS in all brain regions examined between the ages of 4 and 6 months in both WT and Fmr1 null mice. Superimposed on the age-dependent decline in rCPS, we demonstrate a regionally selective elevation in rCPS in Fmr1 null mice. Our results suggest that the process of synaptic pruning during young adulthood may be reflected in decreased rCPS. Our findings support the hypothesis that FMRP is a suppressor of translation in brain in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15901791      PMCID: PMC6724856          DOI: 10.1523/JNEUROSCI.0093-05.2005

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  133 in total

Review 1.  Fragile X: leading the way for targeted treatments in autism.

Authors:  Lulu W Wang; Elizabeth Berry-Kravis; Randi J Hagerman
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

2.  Extinction of an instrumental response: a cognitive behavioral assay in Fmr1 knockout mice.

Authors:  M S Sidorov; D D Krueger; M Taylor; E Gisin; E K Osterweil; M F Bear
Journal:  Genes Brain Behav       Date:  2014-04-30       Impact factor: 3.449

Review 3.  Toward fulfilling the promise of molecular medicine in fragile X syndrome.

Authors:  Dilja D Krueger; Mark F Bear
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

Review 4.  Protein synthesis inhibitors, gene superinduction and memory: too little or too much protein?

Authors:  Jelena Radulovic; Natalie C Tronson
Journal:  Neurobiol Learn Mem       Date:  2007-09-29       Impact factor: 2.877

5.  Elevated ERK/p90 ribosomal S6 kinase activity underlies audiogenic seizure susceptibility in fragile X mice.

Authors:  Kirsty Sawicka; Alexander Pyronneau; Miranda Chao; Michael V L Bennett; R Suzanne Zukin
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-23       Impact factor: 11.205

Review 6.  Lithium: a promising treatment for fragile X syndrome.

Authors:  Zhonghua Liu; Carolyn Beebe Smith
Journal:  ACS Chem Neurosci       Date:  2014-05-15       Impact factor: 4.418

7.  Drosophila fragile X mental retardation protein and metabotropic glutamate receptor A convergently regulate the synaptic ratio of ionotropic glutamate receptor subclasses.

Authors:  Luyuan Pan; Kendal S Broadie
Journal:  J Neurosci       Date:  2007-11-07       Impact factor: 6.167

Review 8.  The translation of translational control by FMRP: therapeutic targets for FXS.

Authors:  Jennifer C Darnell; Eric Klann
Journal:  Nat Neurosci       Date:  2013-04-14       Impact factor: 24.884

Review 9.  Fragile X: a family of disorders.

Authors:  Weerasak Chonchaiya; Andrea Schneider; Randi J Hagerman
Journal:  Adv Pediatr       Date:  2009

Review 10.  Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome.

Authors:  Gül Dölen; Mark F Bear
Journal:  J Physiol       Date:  2008-01-17       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.